190 related articles for article (PubMed ID: 34794793)
1. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients.
Clé DV; Hirayama AV; Alencar AJ; Costa LJ; Feliciano JVP; Mattos ER; Cordeiro AC; Salvino MA; Barros GMN; de Lima M; Scheinberg P; Guerino-Cunha RL
Hematol Transfus Cell Ther; 2021 Nov; 43 Suppl 2(Suppl 2):S3-S12. PubMed ID: 34794793
[TBL] [Abstract][Full Text] [Related]
2. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia.
Seber A; de CastroJunior CG; Kerbauy LN; Hirayama AV; Bonfim C; Fernandes JF; Souza M; Schafell R; Nabhan S; Loggetto SR; Simões BP; Rocha V; de Lima M; Guerino-Cunha RL; Bittencourt H
Hematol Transfus Cell Ther; 2021 Nov; 43 Suppl 2(Suppl 2):S13-S21. PubMed ID: 34794791
[TBL] [Abstract][Full Text] [Related]
3. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation.
Picanço-Castro V; Bonamino MH; Ramos RN; Guerino-Cunha RL; Oliveira TGM; Rego EM
Hematol Transfus Cell Ther; 2021 Nov; 43 Suppl 2(Suppl 2):S54-S63. PubMed ID: 34794798
[TBL] [Abstract][Full Text] [Related]
4. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. V: Manufacture and quality control.
De Santis GC; Langhi Junior DM; Feitoza A; Mendrone Junior A; Kutner JM; Covas DT; Couto SCF; Guerino-Cunha RL; Orellana MD; Rizzo SRCP
Hematol Transfus Cell Ther; 2021 Nov; 43 Suppl 2(Suppl 2):S35-S41. PubMed ID: 34794795
[TBL] [Abstract][Full Text] [Related]
5. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma.
Alencar AJ; Hirayama AV; Clé DV; Salvino MA; Perini G; Arrais C; Baiocchi O; Palma LC; Colturato I; Vaz J; Chiattone R; de Lima M; Filho JS; Nabhan S; Rocha V; Guerino-Cunha RL; Chiattone CS
Hematol Transfus Cell Ther; 2021 Nov; 43 Suppl 2(Suppl 2):S22-S29. PubMed ID: 34794792
[TBL] [Abstract][Full Text] [Related]
6. Associação Brasileira de Hematologia, Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. Review article: Cell therapy in solid tumors.
Nardo M; Motta TC; Colli LM; Avanzi MP
Hematol Transfus Cell Ther; 2021 Nov; 43 Suppl 2(Suppl 2):S78-S83. PubMed ID: 34794801
[TBL] [Abstract][Full Text] [Related]
7. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients.
Maiolino A; Costa LJ; Pasquini M; Crusoe EQ; Vigorito AC; Salvino MA; Seguro FS; Filho JS; Hungria VTM
Hematol Transfus Cell Ther; 2021 Nov; 43 Suppl 2(Suppl 2):S30-S34. PubMed ID: 34794794
[TBL] [Abstract][Full Text] [Related]
8. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies.
Ramos RN; Picanço-Castro V; Oliveira TGM; Mendrone A; De Santis GC; Bonamino MH; Rocha V
Hematol Transfus Cell Ther; 2021 Nov; 43 Suppl 2(Suppl 2):S46-S53. PubMed ID: 34794797
[TBL] [Abstract][Full Text] [Related]
9. A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist.
Ong SY; Baird JH
J Intensive Care Med; 2023 Oct; ():8850666231205264. PubMed ID: 37899577
[TBL] [Abstract][Full Text] [Related]
10. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. Special article: compassionate use and clinical trial on CAR-T cells.
De Santis GC
Hematol Transfus Cell Ther; 2021 Nov; 43 Suppl 2(Suppl 2):S64-S67. PubMed ID: 34794799
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms and management of CAR T toxicity.
Ferreri CJ; Bhutani M
Front Oncol; 2024; 14():1396490. PubMed ID: 38835382
[TBL] [Abstract][Full Text] [Related]
12. Toxicity of Chimeric Antigen Receptor T Cells and its Management.
Wudhikarn K; Soh SY; Huang H; Perales MA
Blood Cell Ther; 2021 Oct; 4(Spec Edition):S1-S7. PubMed ID: 36713468
[TBL] [Abstract][Full Text] [Related]
13. The Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular seeks the implementation of, and access to, the CAR-T cell treatment in Brazil.
Langhi Junior DM; Maiolino A; Chiattone CS; de Souza CA; Covas DT; Costa FF; Guerino-Cunha RL; Pasquini R
Hematol Transfus Cell Ther; 2021 Nov; 43 Suppl 2(Suppl 2):S1-S2. PubMed ID: 34326029
[No Abstract] [Full Text] [Related]
14. Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012.
Hungria VT; Crusoe EQ; Quero AA; Sampaio M; Maiolino A; Bernardo WM
Rev Bras Hematol Hemoter; 2013; 35(3):201-17. PubMed ID: 23904813
[No Abstract] [Full Text] [Related]
15. Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2022. Part I.
Maiolino A; Crusoé EQ; Martinez GA; Braga WMT; de Farias DLC; Bittencourt RI; Neto JVP; Ribeiro GN; Bernardo WM; Tristão L; Magalhaes RJP; Hungria VTM
Hematol Transfus Cell Ther; 2022; 44(3):410-418. PubMed ID: 35970751
[No Abstract] [Full Text] [Related]
16. Guidelines on the treatment of acute myeloid leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: Project guidelines: Associação Médica Brasileira - 2015.
Bittencourt R; Bortolheiro TC; de Lourdes Lopes Ferrari Chauffaille M; Fagundes EM; Pagnano KB; Rego EM; Bernardo WM
Rev Bras Hematol Hemoter; 2016; 38(1):58-74. PubMed ID: 26969776
[No Abstract] [Full Text] [Related]
17. Guidelines on the diagnosis and treatment for acute promyelocytic leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira - 2013.
Pagnano KB; Rego EM; Rohr S; Chauffaille Mde L; Jacomo RH; Bittencourt R; Firmato AB; Fagundes EM; Melo RA; Bernardo W
Rev Bras Hematol Hemoter; 2014; 36(1):71-92. PubMed ID: 24624041
[No Abstract] [Full Text] [Related]
18. Guidelines on sickle cell disease: primary stroke prevention in children and adolescents. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines project: Associação Médica Brasileira - 2021.
Loggetto SR; Veríssimo MPA; Darrigo-Junior LG; Simões RDS; Bernardo WM; Braga JAP
Hematol Transfus Cell Ther; 2022; 44(1):85-94. PubMed ID: 34857507
[No Abstract] [Full Text] [Related]
19. Guidelines on sickle cell disease: secondary stroke prevention in children and adolescents. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular guidelines project: Associação Médica Brasileira - 2022.
Loggetto SR; Veríssimo MPA; Darrigo-Junior LG; Simões R; Bernardo WM; Braga JAP
Hematol Transfus Cell Ther; 2022; 44(2):246-255. PubMed ID: 35305940
[No Abstract] [Full Text] [Related]
20. CAR T-Cell Therapy: Adverse Events and Management.
Adkins S
J Adv Pract Oncol; 2019; 10(Suppl 3):21-28. PubMed ID: 33520343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
